^
Association details:
| Biomarker: | BCL2 underexpression |
|---|---|
| Cancer: | Ewing Sarcoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma
Published date:
01/02/2023
Excerpt:
We observed that the Bcl-2 inhibitor venetoclax improved the activity of nab-paclitaxel in highly resistant Bcl-2-expressing Ewing sarcoma PDX. Overall, our results suggest that low Bcl-2 expression could be used to select patients with Ewing sarcoma sensitive to nab-paclitaxel...
Secondary therapy:
albumin-bound paclitaxel
DOI:
10.1016/j.bcp.2022.115408
